String trimmers help maintain clean lines on lawns and keep weeds at bay. We found the best string trimmer for every job and budget. Our editors and experts handpick every product we feature. We may ...

Abstract: Conventional beamforming with fixed-position antenna (FPA) arrays has a fundamental trade-off between maximizing the signal power (array gain) over a desired direction and simultaneously ...

Replimune (REPL) shares climbed more than 60% in the premarket on Friday after the company announced plans to resubmit a marketing application for its lead asset RP1 in the U.S., following its second ...

Chris Wedel is a fan of all things tech and gadgets. Living in rural Kansas with his wife and two young boys makes finding ways to stay online tricky — not to mention making my homestead smarter.

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

Abstract: In this article, a general introduction to the area of sensor array and multichannel signal processing is provided, including associated activities of the IEEE Signal Processing Society (SPS ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...

Shares of Replimune Group, Inc. (REPL Quick Quote REPL - Free Report) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 7 minutes ...

JavaScript is a crucial web component and a building block for many web apps and websites. Sometimes users can accidentally disable JavaScript, but the browser settings can help you enable it again.

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...